A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
about
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesCIViC databaseThe role of GATA2 in lethal prostate cancer aggressiveness.Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate CancerExtratumoral Heme Oxygenase-1 (HO-1) Expressing Macrophages Likely Promote Primary and Metastatic Prostate Tumor GrowthGATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to ChemotherapyMultinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate CancerFunctional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonistMoving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.The GATA factor revolution in hematology.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesInsulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.Role of steroid receptor and coregulator mutations in hormone-dependent cancers.A Network Biology Approach Identifies Molecular Cross-Talk between Normal Prostate Epithelial and Prostate Carcinoma Cells.FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression.Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine.Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.Breast cancer risk-associated variants at 6q25.1 influence risk of hepatocellular carcinoma in a Chinese population.Integrating Enhancer Mechanisms to Establish a Hierarchical Blood Development Program.Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion.GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells.Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.Insulin Receptor Isoforms in Physiology and Disease: An Updated View.Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer.Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel.GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer.p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.PIASy antagonizes Ras-driven NSCLC survival by promoting GATA2 SUMOylation.
P2860
Q26796704-2FD2C23C-6011-44F4-8280-09A2D7529D32Q27612411-47E1FE78-D525-4DD6-BC88-1574948334C1Q33848134-E872B8E1-DF9E-4B85-BE1D-99573A2B66F7Q34477201-04369AF6-32C8-45D2-9F3A-E80A6DD9EA9FQ36046653-E441C254-075C-4B42-BFE9-B08E8BD273D2Q36257547-7724D346-9287-465A-A90F-C17F1A1F46BBQ36586089-9F77205E-0EB2-4B18-B300-9241D81BB3A3Q36930975-EFC76D10-3558-46E2-9380-2E6613462D2DQ37737611-CB617973-705F-43BC-955A-FFABB7702E35Q38558334-51BB08DC-39A6-495B-B93F-B397041ED359Q38641329-76EB749D-27B5-49AB-802B-14A8657EBB4AQ38682244-1A32204B-2E88-4F08-B39B-B60CD9225C1DQ38736287-DE1D3787-F4D8-4C6F-817D-304920741F79Q38774786-519AC027-A1CF-45B1-AC25-492182EDC296Q38804966-45F8627B-8F5E-4543-BE4D-F9B13C66474CQ39045171-313ADF61-7309-48C4-9695-22A64A152711Q39132961-93830D98-B777-4F2C-BA71-5BC03A3B75F1Q40112666-F0AB2C5E-1D2E-4A1E-82B4-D317B5A5BE73Q40277965-B1DE4706-A32D-4D4B-8217-81E1AD9900C9Q41670964-2F17D672-CFF0-489E-AE28-7031CE9C6D2DQ42052829-47A09C8A-526A-45A1-9967-93B83A711DBFQ42353379-0F79F20C-DD86-4805-B189-04F0B8650F51Q43114885-A96EE381-A8B5-4CB8-B8B2-4D115E191E78Q47295153-F34D91F5-2558-4022-ACC5-05C93606FC18Q47668280-BAEDBA86-0335-462F-929A-899DBB2AB2B2Q48173258-C7AED197-9FBA-4F60-BAA3-3E7AFB636E61Q48533088-AEC61BB1-3DAC-473D-A98D-8607AB587A62Q49890391-EAE58CC4-52B0-4A44-A8BE-426E0C475CECQ49989205-64D7D6BF-114F-41A9-A697-97A4BA3F26C2Q51013016-174B02BD-FFB2-407C-A2CC-5627C234EFD7Q53685182-E01ECD3E-5D78-4E3D-9280-7931B0AE46E4Q53735518-1D4977CA-40CE-4770-B720-F22F18BB8087Q55308600-5467E906-36C7-490D-9542-960267D136CD
P2860
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@ast
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@en
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
@nl
type
label
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@ast
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@en
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
@nl
altLabel
A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
@en
prefLabel
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@ast
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@en
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
@nl
P2093
P2860
P50
P3181
P1433
P1476
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
@en
P2093
Albert Lee
Ben Readhead
Berta Esteve
Carlos Cordon-Cardo
Daniel P Petrylak
Estrelania Williams
Janis de la Iglesia-Vicente
Joel T Dudley
Jose M Silva
Josep Domingo-Domenech
P2860
P304
P3181
P356
10.1016/J.CCELL.2014.11.013
P577
2015-02-09T00:00:00Z